Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells
- 17 December 2008
- journal article
- research article
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 5 (2) , 80-82
- https://doi.org/10.1038/ncprheum0983
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- ITP three R's: regulation, routing, rituximabBlood, 2008
- Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cellsPublished by Elsevier ,2008
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- B-cell targeting in rheumatoid arthritis and other autoimmune diseasesNature Reviews Immunology, 2006
- Very Low-Dose Tolerance with Nucleosomal Peptides Controls Lupus and Induces Potent Regulatory T Cell SubsetsThe Journal of Immunology, 2005
- The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody ImmunotherapyThe Journal of Experimental Medicine, 2004
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa geneBlood, 2002
- T Cell Activation in Rheumatoid Synovium Is B Cell DependentThe Journal of Immunology, 2001
- Antigen-specific interaction between T and B cellsNature, 1985
- Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors.The Journal of Experimental Medicine, 1984